Author Archives: Lu Rahman

#Biotechnology #Clinical trials

Oxeia Biopharmaceuticals announces Phase II trial for concussion treatment

Oxeia Biopharmaceuticals is a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury. It has announced the initiation of a Phase II clinical trial of OXE103 for treating concussion. The Phase II clinical study is being conducted by Dr. Michael Rippee,… Read More

#News

#Compounds #Storage

Innovation to help compound management in drug discovery

Ziath’s new module will enable its Mirage, Cube or Express tube readers to decode Brooks Acoustix tubes. Acoustix is a small sample tube with a screw cap which is increasingly favoured for storage of novel compounds in solution in large compound stores. It is also compatible with the latest generation of Labcyte… Read More

#News

#Assay development & optimisation #Drug discovery

Industry insight on designing assays that deliver hits with higher physiological relevance

DDW is delighted to announce an exclusive event, supported by SPT Labtech, that will allow you to gain knowledge on kinetic assay design and take this forward to produce assays that deliver hits with higher physiological relevance. Pharmacology expert Dr Nick Holliday, chief scientific officer, Excellerate Bioscience, will lead this… Read More

#Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

Novavax updates on COVID-19 vaccine development

Novavax a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has released an update on its COVID-19 vaccine. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with the company’s proprietary Matrix‑M. “Novavax is in a… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines #RNA

SARS-CoV-2 mutations do not appear to increase transmissibility

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers. The analysis of virus genomes from over 46,000 people with COVID-19 from 99 countries is published in Nature Communications. First and corresponding author Dr Lucy… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

Moderna to supply UK government with an extra 2 million vaccine doses

Moderna will supply the UK government with an additional 2 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, beginning in March 2021. The UK government has now secured 7 million doses of mRNA-1273. “We appreciate the collaboration with the UK government as with many other governments and other key… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

COVID-19 Peer Hub combats vaccine avoidance amid pandemic

From March to April 2020, more than 50% of immunisation programmes around the world have reported significant disruptions to their vaccination services. Developed and delivered by The Geneva Learning Foundation, and supported by the Bill & Melinda Gates Foundation, the COVID-19 Peer Hub programme is connecting more than 4000 immunisation… Read More

#Covid-19 #News

#Exhibition #Ingredients / APIs / Fine chemicals

Chemspec Digital 2020 reports virtual event success

The first Chemspec Digital took place online from 11–12 November 2020 and provided a dedicated meeting platform for the global fine and speciality chemicals community. A total of 1,591 attendees from 57 countries logged on to the platform during the two event days to network, conduct business and watch webinar… Read More

#Editor's Choice #News

#Clinical trials #Drug candidates #Drug targets #Life sciences #Therapeutics

One Nucleus announces life science award shortlist

One Nucleus has revealed the finalists of its annual BioNewsRound Award, recognising life science companies with exciting developments. The finalists will pitch in the lead up to Genesis 2020 during which the winner will be announced. Companies and research organisations were nominated for their most important updates from the last… Read More

#News

#Genes #Therapeutics

Global programme to identify scarring gene may shape future therapies

A £1.5 million research programme that aims to achieve scar free healing within a generation has been launched by The Scar Free Foundation, the medical research charity which focuses solely on scarring. The five-year research study led by the University of Bristol will identify the gene(s) that causes scarring and… Read More

#News

#Clinical trials #Covid-19 #Therapeutics

The 100 year-old therapy that may prevent COVID-19 after exposure to the virus

Most media and public attention during the pandemic has focused upon efforts to develop an effective vaccine to prevent COVID-19, which is caused by the novel coronavirus SARS-CoV-2. Some attention has been paid to investigational therapeutics for treating infected patients, such as the antiviral drug remdesivir or the corticosteroid dexamethasone,… Read More

#Covid-19 #Editor's Choice #News